Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.49 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741356 | 0.96 | HTR6 (0.49) | HTR6RORCCNR1MAPKAPK2LMNA | |
| SCHEMBL6741207 | 0.93 | HTR6 (0.50) | HTR6RORCCNR1MAPKAPK2LMNA | |
| SCHEMBL6744534 | 0.91 | HTR6 (0.59) | HTR6RORCCNR1 | |
| SCHEMBL6744293 | 0.90 | HTR6 (0.50) | HTR6RORCCNR1MAPKAPK2DDR1 | |
| SCHEMBL6741345 | 0.89 | HTR6 (0.51) | HTR6RORCCNR1MAPKAPK2LMNA | |
| SCHEMBL6743687 | 0.89 | HTR6 (0.61) | HTR6 | |
| SCHEMBL6746878 | 0.88 | HTR6 (0.52) | HTR6RORCCNR1LMNAGFER | |
| SCHEMBL6743164 | 0.88 | RORC (0.41) | HTR6RORCLMNAGFERSMN1; SMN2 | |
| SCHEMBL6741349 | 0.88 | HTR6 (0.62) | HTR6 | |
| SCHEMBL6744515 | 0.87 | RORC (0.41) | HTR6RORCLMNAGFERSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579870-B2 | 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity | PHARMACIA & UPJOHN COMPANY | 2003-06-17 | — | — | US | claimed |
| US-20020037892-A1 | Bis-arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-03-28 | — | — | US | claimed |
| US-6579870-B2 | 5-(1,4-diazepan-1-yl)-2-((3 -fluorophenyl)sulfonyl)phenylamine for example; treatment of diseases or disorders of the central nervous system; modulation of serotonin (5-HT) activity | PHARMACIA & UPJOHN COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20020037892-A1 | Bis-arylsulfones | PHARMACIA & UPJOHN COMPANY | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037892-A1 | Bis-arylsulfones | PMP22, ARSA, CLN6 | HTR6 35/4885RORC 387/4885CNR1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.